Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
ABSTRACT Ziftomenib, a potent, highly selective, oral menin inhibitor, has demonstrated significant clinical benefit and deep responses in relapsed and/or refractory (R/R) nucleophosmin 1‐mutated (NPM1‐m) acute myeloid leukemia (AML) patients. Here we present data from analyses conducted to characte...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wiley
2026-05-01
|
| Serier: | CPT: Pharmacometrics & Systems Pharmacology |
| Online adgang: | https://doi.org/10.1002/psp4.70244 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|